Loading…
C4 Therapeutics, Inc. is projected to rise to $4.67 by 2027, a +34% move from its current price of $3.48. CCCC is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $3.36 | $3.48 | $3.61 | +0.12% |
| Aug 4 | $3.31 | $3.49 | $3.67 | +0.24% |
| Aug 5 | $3.28 | $3.49 | $3.72 | +0.37% |
| Aug 6 | $3.25 | $3.50 | $3.76 | +0.49% |
| Aug 7 | $3.22 | $3.50 | $3.80 | +0.61% |
| Aug 8 | $3.20 | $3.51 | $3.84 | +0.73% |
| Aug 9 | $3.18 | $3.51 | $3.87 | +0.86% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.18 | $3.51 | $3.87 | +0.86% |
| Week 2 | $3.08 | $3.54 | $4.06 | +1.72% |
| Week 3 | $3.02 | $3.57 | $4.23 | +2.59% |
| Week 4 | $2.96 | $3.60 | $4.37 | +3.47% |
| Week 5 | $2.92 | $3.63 | $4.51 | +4.36% |
| Week 6 | $2.89 | $3.66 | $4.65 | +5.25% |
| Week 7 | $2.86 | $3.69 | $4.78 | +6.15% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1.
The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co.
Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
CCCC is a clinical-stage biopharmaceutical company focused on protein degradation therapies. The stock currently trades at $3.66 with a market capitalization of $404.68M and is ranked 3008 by market cap. The current price sits within a 30-day range of $2.88 to $4.66, and the stock’s price action is framed by a bullish longer-term outlook in the provided forecast data.
Forecasts show the 2026 average price at $3.66, with subsequent years projecting higher averages (e.g., 2027 $4.95, 2028 $6.49, up to 2050 $34.99), indicating meaningful upside potential over the longer horizon.
A major floor 32.5% below — a decisive break under it would weaken the trend.
Price is testing support right now (2.3% away) — a key level to hold.
The nearest ceiling, 34.2% above — a clean break opens room to run.
A major ceiling 47.1% above — clearing it would confirm fresh momentum.
Key CCCC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CCCC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.56 | Sell | $3.56 | Sell |
| MA 10 | $3.60 | Sell | $3.62 | Sell |
| MA 20 | $3.79 | Sell | $3.73 | Sell |
| MA 50 | $3.91 | Sell | $3.73 | Sell |
| MA 100 | $3.39 | Buy | $3.46 | Buy |
| MA 200 | $2.86 | Buy | $3.13 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 41.93 | Neutral |
| Stoch RSI (14) | 43.08 | Neutral |
| CCI (20) | -91.62 | Neutral |
| Williams %R (14) | -81.40 | Info |
| MACD (12,26,9) | -0.03 | Sell |
| ROC (12) | -8.42 | Sell |
| Bollinger %B (20,2) | 0.22 | Neutral |
| Stochastic %K (14) | 18.60 | Buy |
| TRIX (15) | -0.35 | Sell |
| Awesome (5,34) | -0.39 | Sell |
| Ultimate (7,14,28) | 37.33 | Neutral |
| Momentum (10) | -0.21 | Sell |
| Aroon Osc (25) | -68.00 | Sell |
| Hull MA (9) | 3.54 | Sell |
| ADX (14) | 14.93 | Neutral |
| ATR (14) | 0.14 | Info |
The 30-day technical picture is bullish overall. RSI14 is 50, with the 50-day simple moving average at $3.90 and the 200-day simple moving average at $2.85. Support is listed at $3.40 and resistance at $4.67, framing a near-term trading range within the 30-day window of $2.88 to $4.66.
Annualized volatility is high at 70%, underscoring substantial price movement potential within the month.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.71 | $3.48 | $4.96 | 0% | Neutral | |
| $3.61 | $4.67 | $6.46 | +34% | Bullish | |
| $4.58 | $6.16 | $8.94 | +77% | Bullish | |
| $4.83 | $6.72 | $10.12 | +93% | Bullish | |
| $4.95 | $7.09 | $11.01 | +104% | Bullish | |
| $5.11 | $7.53 | $12.02 | +116% | Bullish | |
| $4.75 | $7.17 | $11.72 | +106% | Bullish | |
| $6.03 | $9.32 | $15.56 | +168% | Bullish | |
| $7.63 | $12.06 | $20.55 | +247% | Bullish | |
| $7.30 | $11.80 | $20.48 | +239% | Bullish | |
| $10.12 | $18.10 | $33.88 | +420% | Bullish | |
| $15.17 | $32.63 | $68.06 | +838% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.71 | $3.48 | $4.18 | +0.00% |
| September 2026 | $3.01 | $3.60 | $4.45 | +3.47% |
| October 2026 | $3.22 | $3.89 | $4.87 | +8.01% |
| November 2026 | $3.23 | $3.92 | $4.97 | +0.90% |
| December 2026 | $3.16 | $3.87 | $4.96 | -1.37% |
Click any year to see its month-by-month CCCC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, CCCC is projected to trade between $1.71 and $4.96, averaging $3.48 — a potential gain of 0% from today's $3.48. A consolidation phase looks the most probable path here.
C4 Therapeutics, Inc.'s 2027 outlook centres on $4.67, within a $3.61 to $6.46 range. That is up +34% on the projected 2026 average. That marks a +34% change versus current levels. Momentum favours further upside here.
By 2028, CCCC could reach as high as $8.94, with a base case around $6.16 and support toward $4.58 — roughly +77% from $3.48. Buyers look set to stay in control over this stretch.
Expect CCCC to range from $4.83 to $10.12 through 2029. The $6.72 average target implies a +93% move from current prices. That is up +9% on the projected 2028 average. Momentum favours further upside here.
The CCCC price prediction for 2030 points to an average of $7.09 (low $4.95, high $11.01) — a potential gain of +104% on today's $3.48. Buyers look set to stay in control over this stretch.
In 2031, CCCC is projected to trade between $5.11 and $12.02, averaging $7.53 — a potential gain of +116% from today's $3.48. That is up +6% on the projected 2030 average. Momentum favours further upside here.
C4 Therapeutics, Inc.'s 2032 outlook centres on $7.17, within a $4.75 to $11.72 range. That is -5% versus the projected 2031 average. That marks a +106% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, CCCC could reach as high as $15.56, with a base case around $9.32 and support toward $6.03 — roughly +168% from $3.48. Momentum favours further upside here.
Expect CCCC to range from $7.63 to $20.55 through 2034. The $12.06 average target implies a +247% move from current prices. That is up +29% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The CCCC price prediction for 2035 points to an average of $11.80 (low $7.30, high $20.48) — a potential gain of +239% on today's $3.48. Momentum favours further upside here.
In 2040, CCCC is projected to trade between $10.12 and $33.88, averaging $18.10 — a potential gain of +420% from today's $3.48. That is up +53% on the projected 2035 average. Buyers look set to stay in control over this stretch.
C4 Therapeutics, Inc.'s 2050 outlook centres on $32.63, within a $15.17 to $68.06 range. That is up +80% on the projected 2040 average. That marks a +838% change versus current levels. Momentum favours further upside here.
Investing $1,000 in CCCC today (≈ 287.356322 CCCC) could be worth
$9,377.2
+$8,377.2 (+838%) by 2050 · US Dollar
Based on the average projected CCCC price of $32.63 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CCCCwould be worth at today's price.
$1,000 invested in CCCC on Jul 31, 2025 (≈ 487.804889 CCCC) would be worth
$1,697.56
+$697.56 (+69.8%) today · 1.70× · US Dollar
Based on a CCCC entry price of $2.05 vs. today's $3.48.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.4 | $1,023.53 | +2.4% |
| 1 month ago | $4.34 | $801.84 | -19.8% |
| 3 months ago | $2.92 | $1,191.78 | +19.2% |
| 6 months ago | $1.88 | $1,851.06 | +85.1% |
| 1 year ago | $2.05 | $1,697.56 | +69.8% |
| All time (5.0y) ago | $45.94 | $75.75 | -92.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CCCC forecast.
Our base-case forecast reaches $7.00 around 2030.
Implied market cap at $7.00: $773.97M
The multi-year forecast shows a trend of upside over time. The 2026 forecast has a min of $1.71, an avg of $3.66, and a max of $5.22, with a neutral sentiment. From 2027 onward, the path is bullish, with the avg rising to $4.95 (ROI 35.2%), then to $6.49 (ROI 77.4%) in 2028 and $7.11 (ROI 94.3%) in 2029, and $7.51 (ROI 105.3%) in 2030.
The forecast continues to climb: 2031 avg $7.96 (ROI 117.3%), 2032 $7.64 (ROI 108.8%), and 2033 $9.96 (ROI 172%), followed by 2034 $12.81 (ROI 249.9%) and 2035 $12.56 (ROI 243.3%). By 2040, the avg is $19.34 (ROI 428.5%), and by 2050 the avg reaches $34.99 (ROI 856.1%). Sentiment remains bullish in 2027 through 2050.
These figures are estimates, not guarantees, and reflect a potential long-run upside with varying yearly ranges.
Tap a question to reveal the answer.
In 2030, the forecast shows a min of $5.25, an avg of $7.51, and a max of $11.66, with an ROI of 105.3% and bullish sentiment.
The forecast shows bullish sentiment in most years after 2026, with rising average prices and positive ROIs (e.g., 2027 ROI 35.2%, 2028 ROI 77.4%, 2029 ROI 94.3%, culminating in a 2050 ROI of 856.1%). These are estimates, not guarantees.
Yes. The 2034 max is $21.77, and the 2033 max is $16.59, indicating a potential pathway above $20 in the mid-2030s if the forecast unfolds.
Current price: $3.66. Market capitalization: $404.68M.
The 2050 forecast shows an average price of $34.99, a min of $16.37, a max of $72.77, and a ROI of 856.1%, with bullish sentiment.
C4 Therapeutics, Inc. Community Discussion
0Share your C4 Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.